Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00724048 · ClinicalTrials.gov registry record · Phase 2
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
A Phase 2 study of Huntington Disease, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 227
- Enrollment target
- 20
- Study locations
NCT00724048 is a Phase 2 study of Huntington Disease that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 227 participants, below the 629-participant average among 35 other Huntington Disease trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT00724048, a Phase 2 study of Huntington Disease, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 227 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG ACR16
Study Locations (20)
New York
- Albany Medical College - Albany
- North Shore-LIJ Health System - Manhasset
- University of Rochester - Rochester
Maryland
- University of Maryland School of Medicine - Baltimore
- Johns Hopkins University - Baltimore
Ohio
- University of Cincinnati - Cincinnati
- Ohio State University Parkinson's Center - Columbus
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California - San Diego
Colorado
- Colorado Neurological Institute - Littleton
Florida
- University of South Florida - Tampa
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2008-10-24 |
| Est. Completion | 2010-07-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00724048
The ClinicalTrials.gov registry entry for NCT00724048 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 629-participant average among 35 other Huntington Disease trials with a reported enrollment target (64% lower). The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00724048 reports 20 study locations spanning 16 distinct geographic areas - top geographies include New York, Maryland, Ohio.
Frequently Asked Questions
What is clinical trial NCT00724048 about?
NCT00724048 is a clinical study titled "A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease". The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease.
What is the current status of trial NCT00724048?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 227 participants. The study started on 2008-10-24. Estimated completion is 2010-07-26.
What conditions does trial NCT00724048 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT00724048?
The interventions under investigation include: Placebo (OTHER), ACR16 (DRUG).
Who is sponsoring clinical trial NCT00724048?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00724048 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
ACTIVE NOT RECRUITING · Phase 2
-
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
ACTIVE NOT RECRUITING · Phase 2
-
Creatine Safety and Tolerability in Premanifest HD: PRECREST
COMPLETED · Phase 2
-
Atomoxetine and Huntington's Disease
COMPLETED · Phase 2
-
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
COMPLETED · Phase 2
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.